Moderna (NASDAQ:MRNA) Price Target Cut to $197.00

Moderna (NASDAQ:MRNAGet Rating) had its price target reduced by research analysts at Morgan Stanley from $199.00 to $197.00 in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports. The brokerage presently has an “equal weight” rating on the stock. Morgan Stanley’s price target would indicate a potential upside of 5.44% from the stock’s current price.

MRNA has been the subject of a number of other reports. SVB Leerink boosted their price objective on shares of Moderna from $70.00 to $77.00 and gave the stock an “underperform” rating in a report on Monday, August 1st. Piper Sandler cut their target price on shares of Moderna from $348.00 to $214.00 and set an “overweight” rating for the company in a research report on Tuesday, May 17th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Moderna has an average rating of “Hold” and an average target price of $226.92.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $186.84 on Thursday. Moderna has a twelve month low of $115.61 and a twelve month high of $497.49. The firm has a market cap of $74.32 billion, a P/E ratio of 5.69, a PEG ratio of 1.05 and a beta of 1.61. The company has a 50 day moving average of $152.33 and a 200 day moving average of $152.85. The company has a quick ratio of 1.56, a current ratio of 1.99 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNAGet Rating) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported $5.24 earnings per share for the quarter, topping analysts’ consensus estimates of $4.73 by $0.51. Moderna had a net margin of 61.12% and a return on equity of 94.76%. The company had revenue of $4.73 billion during the quarter, compared to analyst estimates of $3.95 billion. During the same period in the previous year, the business earned $6.46 EPS. The firm’s revenue for the quarter was up 8.7% on a year-over-year basis. As a group, research analysts expect that Moderna will post 27.29 EPS for the current fiscal year.

Insider Activity

In other news, insider Juan Andres sold 195 shares of the business’s stock in a transaction on Tuesday, May 10th. The shares were sold at an average price of $133.71, for a total transaction of $26,073.45. Following the completion of the sale, the insider now owns 9,309 shares of the company’s stock, valued at approximately $1,244,706.39. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, President Stephen Hoge sold 234 shares of the business’s stock in a transaction on Tuesday, May 10th. The shares were sold at an average price of $133.71, for a total transaction of $31,288.14. Following the completion of the sale, the president now owns 1,622,820 shares of the company’s stock, valued at approximately $216,987,262.20. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Juan Andres sold 195 shares of the business’s stock in a transaction on Tuesday, May 10th. The shares were sold at an average price of $133.71, for a total transaction of $26,073.45. Following the sale, the insider now directly owns 9,309 shares of the company’s stock, valued at approximately $1,244,706.39. The disclosure for this sale can be found here. Insiders sold a total of 606,029 shares of company stock valued at $91,997,025 in the last 90 days. Company insiders own 17.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of MRNA. Vestmark Advisory Solutions Inc. boosted its holdings in Moderna by 108.5% in the 4th quarter. Vestmark Advisory Solutions Inc. now owns 1,084 shares of the company’s stock worth $275,000 after buying an additional 564 shares during the period. D.A. Davidson & CO. boosted its holdings in Moderna by 28.9% in the 4th quarter. D.A. Davidson & CO. now owns 7,143 shares of the company’s stock worth $1,814,000 after buying an additional 1,600 shares during the period. CWM LLC bought a new position in Moderna in the 4th quarter worth $810,000. Capital Investment Advisory Services LLC boosted its holdings in Moderna by 38.0% in the 4th quarter. Capital Investment Advisory Services LLC now owns 998 shares of the company’s stock worth $253,000 after buying an additional 275 shares during the period. Finally, AGF Investments Inc. boosted its holdings in Moderna by 89.4% in the 4th quarter. AGF Investments Inc. now owns 2,826 shares of the company’s stock worth $718,000 after buying an additional 1,334 shares during the period. Institutional investors own 61.20% of the company’s stock.

Moderna Company Profile

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Further Reading

Analyst Recommendations for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.